Literature DB >> 3203042

The pharmacokinetics of oral nifedipine--a population study.

A G Renwick1, D R Robertson, B Macklin, V Challenor, D G Waller, C F George.   

Abstract

1. The pharmacokinetics and metabolism of nifedipine have been studied in a population of 59 young male volunteers following administration of a 10 mg capsule. 2. The area under the plasma concentration-time curves (AUC) for nifedipine demonstrated a skewed but not a bimodal distribution (mean 154 ng ml-1 h; range 54-306 ng ml-1h). 3. Calculation of the ratio of the AUC of nifedipine to the AUC of its nitropyridine metabolite did not separate those individuals with high AUC values of nifedipine from the remainder of the population. 4. Similarly there was no evidence for bimodality in the excretion of the major urinary metabolite. Those subjects with high plasma AUC values for nifedipine excreted similar amounts to the remainder of the population. 5. In contrast to a previous study using a 20 mg oral dose, there was no evidence of polymorphism in the pharmacokinetics or metabolism of nifedipine following a single 10 mg oral dose.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3203042      PMCID: PMC1386447          DOI: 10.1111/j.1365-2125.1988.tb05256.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  The trans-hepatic extraction of nifedipine.

Authors:  V F Challenor; D G Waller; A G Renwick; B S Gruchy; C F George
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

2.  [Clinical study on the pharmacokinetics of radioactively labelled 4-(2'-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid dimethyl ester].

Authors:  F A Horster; B Duhm; W Maul; H Medenwald; K Patzschke; L A Wegner
Journal:  Arzneimittelforschung       Date:  1972-02

3.  Protein binding of nifedipine.

Authors:  J Otto; L J Lesko
Journal:  J Pharm Pharmacol       Date:  1986-05       Impact factor: 3.765

4.  Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man.

Authors:  C H Kleinbloesem; P van Brummelen; H Faber; M Danhof; N P Vermeulen; D D Breimer
Journal:  Biochem Pharmacol       Date:  1984-11-15       Impact factor: 5.858

5.  The first pass metabolism of nifedipine in man.

Authors:  D G Waller; A G Renwick; B S Gruchy; C F George
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

6.  Liquid chromatographic determination of nifedipine in plasma and of its main metabolite in urine.

Authors:  C H Kleinbloesem; J Van Harten; P Van Brummelen; D D Breimer
Journal:  J Chromatogr       Date:  1984-06-08

7.  Oxidation of 1,4-dihydropyridines by prostaglandin synthase and the peroxidic function of cytochrome P-450. Demonstration of a free radical intermediate.

Authors:  C Bäärnhielm; G Hansson
Journal:  Biochem Pharmacol       Date:  1986-05-01       Impact factor: 5.858

8.  Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism.

Authors:  F P Guengerich; M V Martin; P H Beaune; P Kremers; T Wolff; D J Waxman
Journal:  J Biol Chem       Date:  1986-04-15       Impact factor: 5.157

9.  The intra- and inter-subject variability of nifedipine pharmacokinetics in young volunteers.

Authors:  J Lobo; D B Jack; M J Kendall
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

10.  Cytochrome P-450-dependent oxidation of felodipine--a 1,4-dihydropyridine--to the corresponding pyridine.

Authors:  C Bäärnhielm; I Skånberg; K O Borg
Journal:  Xenobiotica       Date:  1984-09       Impact factor: 1.908

View more
  9 in total

1.  Ethnic differences in the pharmacokinetics of oral nifedipine.

Authors:  C H Ahsan; A G Renwick; B Macklin; V F Challenor; D G Waller; C F George
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

2.  An examination of a possible pharmacokinetic interaction between nifedipine and antipyrine.

Authors:  T Edeki; A Johnston; P Turner
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  A population study of the pharmacokinetics of felodipine.

Authors:  E Blychert; B Edgar; D Elmfeldt; T Hedner
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

Review 4.  Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics.

Authors:  Mei-Ling Chen
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  Control of vascular tone in isolated mesenteric arterial segments from hypertensive patients.

Authors:  N Hutri-Kähönen; M Kähönen; X Wu; J Sand; I Nordback; J Taurio; I Pörsti
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

6.  Progesterone blocks multiple routes of ion flux.

Authors:  Brooke G Kelley; Paul G Mermelstein
Journal:  Mol Cell Neurosci       Date:  2011-07-19       Impact factor: 4.314

7.  Factors affecting the absolute bioavailability of nifedipine.

Authors:  T J Rashid; U Martin; H Clarke; D G Waller; A G Renwick; C F George
Journal:  Br J Clin Pharmacol       Date:  1995-07       Impact factor: 4.335

8.  The influence of posture on the pharmacokinetics of orally administered nifedipine.

Authors:  A G Renwick; C H Ahsan; V F Challenor; R Daniels; B S Macklin; D G Waller; C F George
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

9.  Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin.

Authors:  W Mück; S Unger; K Kawano; G Ahr
Journal:  Br J Clin Pharmacol       Date:  1998-06       Impact factor: 4.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.